肾脏替代疗法治疗肝肾综合征的研究进展

陈丽; 梅永; 杨亦彬; 曹明燕

doi:10.3969/j.issn.1001-5256.2016.03.046

肾脏替代疗法治疗肝肾综合征的研究进展

DOI: 10.3969/j.issn.1001-5256.2016.03.046

1. 遵义医学院附属医院肾内科
2. 遵义医学院第三附属医院肝胆外科

详细信息

中图分类号: R575.2;R692
计量
- 文章访问数: 2067
- HTML全文浏览量: 33
- PDF下载量: 376
- 被引次数: 0
出版历程
- 出版日期: 2016-03-20

Research advances in renal replacement therapy for hepatorenal syndrome

Department of Nephropathy, Affiliated Hospital of Zunyi Medical University

摘要

摘要:
肝肾综合征(HRS)是终末期肝病的严重并发症,其总体治疗效果并不理想,生存时间短,预后差。肾脏替代治疗是目前主要的非移植治疗手段之一,但其疗效仍然存在争议。叙述了HRS的概况及肾脏替代治疗在治疗HRS临床疗效的最新进展。认为肾脏替代治疗不应作为HRS的常规治疗措施,但可用于计划性肝移植患者的移植前过渡性治疗,以及对血管收缩药物无效的非肝移植患者的短期治疗。
- 肝硬化 /
- 肝肾综合征 /
- 肾替代疗法 /
- 综述
Abstract:
Hepatorenal syndrome( HRS) is a serious complication of the end- stage liver disease. The overall treatment outcome of HRS is not satisfactory,with a short survival time and a poor prognosis. Currently,renal replacement therapy is one of the main non- transplantation therapeutic methods,but its clinical effect remains controversial. This review summarizes the research on HRS and advances in the clinical effect of renal replacement therapy for HRS,and points out that renal replacement therapy is not suitable as the conventional therapy for HRS,but it can be applied as the pre- transplantation transitional treatment for patients with a plan for liver transplantation,as well as the short- term treatment for non- transplantation patients who do not respond to vasoconstrictors.
- liver cirrhosis /
- hepatorenal syndrome /
- renal replacement therapy /
- review

HTML全文

参考文献(45)

[1]BELCHER JM,COCA SG,PARIKH CR.Creatinine change on vasoconstrictors as mortality surrogate in hepatorenal syndrome:systematic review&Meta-analysis[J].PLo S One,2015,10(8):e0135625.

[2]ALLEGRETTI AS,ORTIZ G,WENGER J,et al.Prognosis of acute kidney injury and hepatorenal syndrome in patients with cirrhosis:a prospective cohort study[J].Int J Nephrol,2015,2015:108139.

[3]LOW G,ALEXANDER GJ,LOMAS DJ.Hepatorenal syndrome:aetiology,diagnosis,and treatment[J].Gastroenterol Res Pract,2015,2015:207012.

[4]WONG F,NADIM MK,KELLUM JA,et al.Working party proposal for a revised classification system of renal dysfunction in patients with cirrhosis[J].Gut,2011,60(5):702-709.

[5]NADIM MK,KELLUM JA,DAVENPORT A,et al.Hepatorenal syndrome:the 8th international consensus conference of the Acute Dialysis Quality Initiative(ADQI)group[J].Crit Care,2012,16(1):r23.

[6]GINS P,SCHRIER RW.Renal failure in cirrhosis[J].N Engl J Med,2009,361(13):1279-1290.

[7]DUNDAR HZ,YILMAZLAR T.Management of hepatorenal syndrome[J].World J Nephrol,2015,4(2):277-286.

[8]WADEI HM.Hepatorenal syndrome:a critical update[J].Semin Respir Crit Care Med,2012,33(1):55-69.

[9]HAAD CR,RODRIGUEZ-BENOT A,MARTINEZ-VAQUERA S,et al.Combined liver-kidney transplantation:survey of a single center in Spain[J].Transplant Proc,2013,45(10):3640-3643.

[10]LEE JP,KWON HY,PARK JI,et al.Clinical outcomes of patients with hepatorenal syndrome after living donor liver transplantation[J].Liver Transpl,2012,18(10):1237-1244.

[11]SUSSMAN AN,BOYER TD.Management of refractory ascites and hepatorenal syndrome[J].Curr Gastroenterol Rep,2011,13(1):17-25.

[12]CHOK KS,FUNG JY,CHAN SC,et al.Outcomes of living donor liver transplantation for patients with preoperative type 1 hepatorenal syndrome and acute hepatic decompensation[J].Liver Transpl,2012,18(7):779-785.

[13]LAVAYSSIRE L,KALLAB S,CARDEAU-DESANGLES I,et al.Impact of molecular adsorbent recirculating system on renal recovery in type-1 hepatorenal syndrome patients with chronic liver failure[J].J Gastroenterol Hepatol,2013,28(6):1019-1024.

[14]HEIDEMANN J,BARTELS C,BERSSENBRGGE C,et al.Hepatorenal syndrome:outcome of response to therapy and predictors of survival[J].Gastroenterol Res Pract,2015,2015:457613.

[15]GINS P,ANGELI P,LENZ K,et al.EASL clinical practice guidelines on the management of ascites,spontaneous bacterial peritonitis,and hepatorenal syndrome in cirrhosis[J].J Hepatol,2010,53(3):397-417.

[16]KISER TH.Hepatorenal syndrome[J].Int J Clin Med,2014,5:102-110.

[17]ARROYO V,GINS P,GERBES AL,et al.Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis.International Ascites Club[J].Hepatology,1996,23(1):164-176.

[18]SALERNO F,GERBES A,GINS P,et al.Diagnosis,prevention and treatment of hepatorenal syndrome in cirrhosis[J].Gut,2007,56(9):1310-1318.

[19]FAGUNDES C,PPIN MN,GUEVARA M,et al.Urinary neutrophil gelatinase-associated lipocalin as biomarker in the differential diagnosis of impairment of kidney function in cirrhosis[J].J Hepatol,2012,57(2):267-273.

[20]VERNA EC,BROWN RS,FARRAND E,et al.Urinary neutrophil gelatinase-associated lipocalin predicts mortality and identifies acute kidney injury in cirrhosis[J].Dig Dis Sci,2012,57(9):2362-2370.

[21]FAGUNDES C,GINS P.Hepatorenal syndrome:a severe,but treatable,cause of kidney failure in cirrhosis[J].Am J Kidney Dis,2012,59(6):874-885.

[22]SOL AE,GUEVARA M,GINS P.Current treatment strategies for hepatorenal syndrome[J].Clin Liver Dis,2013,2(3):136-139.

[23]SAMPAIO MS,MARTIN P,BUNNAPRADIST S.Renal dysfunction in end-stage liver disease and post-liver transplant[J].Clin Liver Dis,2014,18(3):543-560.

[24]FABRIZI F,AGHEMO A,MESSA P.Hepatorenal syndrome and novel advances in its management[J].Kidney Blood Press Res,2013,37(6):588-601.

[25]LENZ K,BUDER R,KAPUN L,et al.Treatment and management of ascites and hepatorenal syndrome:an update[J].Therap Adv Gastroenterol,2015,8(2):83-100.

[26]ACHIM C,ZGURA,ZGURD,et al.Current therapies in hepatorenal syndrome[J].Rom J Intern Med,2014,52(4):201-215.

[27]SAGI SV,MITTAL S,KASTURI KS,et al.Terlipressin therapy for reversal of type 1 hepatorenal syndrome:a meta-analysis of randomized controlled trials[J].J Gastroenterol Hepatol,2010,25(5):880-885.

[28]GHOSH S,CHOUDHARY NS,SHARMA AK,et al.Noradrenaline vs terlipressin in the treatment of type 2 hepatorenal syndrome:a randomized pilot study[J].Liver Int,2013,33(8):1187-1193.

[29]CHOLONGITAS E,SENZOLO M,PATCH D,et al.Cirrhotics admitted to intensive care unit:the impact of acute renal failure on mortality[J].Eur J Gastroenterol Hepatol,2009,21(7):744-750.

[30]BARBANO B,SARDO L,GIGANTE A,et al.Pathophysiology,diagnosis and clinical management of hepatorenal syndrome:from classic to new drugs[J].Curr Vasc Pharmacol,2014,12(1):125-135.

[31]MELTZER J,BRENTJENS TE.Renal failure in patients with cirrhosis:hepatorenal syndrome and renal support strategies[J].Curr Opin Anaesthesiol,2010,23(2):139-144.

[32]WONG LP,BLACKLEY MP,ANDREONI KA,et al.Survival of liver transplant candidates with acute renal failure receiving renal replacement therapy[J].Kidney Int,2005,68(1):362-370.

[33]CARACENI P,SANTI L,MIRICI F,et al.Long-term treatment of hepatorenal syndrome as a bridge to liver transplantation[J].Dig Liver Dis,2011,43(3):242-245.

[34]WITZKE O,BAUMANN M,PATSCHAN D,et al.Which patients benefit from hemodialysis therapy in hepatorenal syndrome?[J].J Gastroenterol Hepatol,2004,19(12):1369-1373.

[35]BELCHER JM.Is there a role for dialysis in patients with hepatorenal syndrome who are not liver transplant candidates?[J].Semin Dial,2014,27(3):288-291.

[36]GUEUTIN V,MEFTAH A,DESBUISSONS G,et al.Hepatorenal syndrome:focus[J].Nephrol Ther,2013,9(7):471-480.

[37]CAPLING RK,BASTANI B.The clinical course of patients with type 1 hepatorenal syndrome maintained on hemodialysis[J].Ren Fail,2004,26(5):563-568.

[38]DAVENPORT A,BOUMAN C,KIRPALANI A,et al.Delivery of renal replacement therapy in acute kidney injury:what are the key issues?[J].Clin J Am Soc Nephrol,2008,3(3):869-875.

[39]BELLOMO R,CASS A,COLE L,et al.Intensity of continuous renal-replacement therapy in critically ill patients[J].N Engl J Med,2009,361(17):1627-1638.

[40]The VA/NIH Acute Renal Failure Trial Network.Intensity of renal support in critically ill patients with acute kidney injury[J].N Engl J Med,2008,359(1):7-20.

[41]WONG F.Treatment to improve acute kidney injury in cirrhosis[J].Curr Treat Options Gastroenterol,2015,13(2):235-248.

[42]GONWA TA,WADEI HM.The challenges of providing renal replacement therapy in decompensated liver cirrhosis[J].Blood Purif,2012,33(1-3):144-148.

[43]OLIVERA-MARTINEZ M,SAYLES H,VIVEKANANDAN R,et al.Hepatorenal syndrome:are we missing some prognostic factors?[J].Dig Dis Sci,2012,57(1):210-214.

[44]ELIZABETH PARSONS C,NELSON R,BOOK LS,et al.Renal replacement therapy in infants and children with hepatorenal syndrome awaiting liver transplantation:a case-control study[J].Liver Transpl,2014,20(12):1468-1474.

[45]SOURIANARAYANANE A,RAINA R,GARG G,et al.Management and outcome in hepatorenal syndrome:need for renal replacement therapy in non-transplanted patients[J].Int Urol Nephrol,2014,46(4):793-800.

施引文献

资源附件(0)

访问统计